Novonesis A S (NVZMF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the NovoNazis Q1 2025 conference call. I am Healy, the chorus call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Tobias Cornelius Björklund, head of investor relations. Please go ahead. Thank you very much, operator, and welcome everyone to the NovoNesis conference call for the first quarter of 2025. My name is Tobias Björklund, and as I said, I'm heading up our investor relation activities here at NovoNesis. In this call, our CEO, Esther Baggett, and our CFO, Rainer Lehmann, will review our performance for the year, as well as the outlook for 2025. Also attending today's calls are Amy Byrick, EVP of Human Health BioSolutions, Tina Feiner, EVP of Planetary Health Biosolutions, and Klaus-Krone Fuglsang, Chief Scientific Officer. The conference call will take about 45 minutes, including Q&A. Please change to the next slide. And this is, as usual, a slide where I would like to remind you that the information presented during the call is unaudited, and that management may make forward-looking statements. These statements are based on current expectations and beliefs, and they involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statement. With that, I will now hand you over to our CEO, Esther Baggett. Esther, please. Thank you. Thank you, Tobias. And welcome, everyone. Thank you for join...